Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Other Accumulated Expenses for 7 consecutive years, with $109350.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 14.37% year-over-year to $109350.0; the TTM figure through Mar 2026 stood at $109350.0 (down 14.37% YoY), while the FY2025 annual figure was $212927.0, up 162.87% from the prior year.
• Other Accumulated Expenses eased to $109350.0 in Q1 2026 per IKT's latest filing, from $212927.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.7 million in Q1 2023 and bottomed at $100.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $212400.2 across 5 years, with a median of $32671.0 in 2022.
• On a YoY basis, Other Accumulated Expenses climbed as much as 14920.58% in 2023 and fell as far as 99.69% in 2023.
• Inhibikase Therapeutics' Other Accumulated Expenses stood at $9920.0 in 2022, then surged by 936.46% to $102817.0 in 2023, then fell by 21.22% to $81000.0 in 2024, then surged by 162.87% to $212927.0 in 2025, then plunged by 48.64% to $109350.0 in 2026.
• Business Quant data shows IKT's Other Accumulated Expenses at $109350.0 in Q1 2026, $212927.0 in Q4 2025, and $116166.0 in Q3 2025.